Rilpivirine is an antiviral medicine used to treat HIV infections. It works by stopping the virus from copying itself. It's often used with other HIV medicines to prevent the virus from becoming resistant.
Every report comes from a Lived member, sent anonymously.
Have you tried Rilpivirine for HIV Infection?
Rilpivirine is a prescription antiviral medicine used to treat HIV-1, the most common type of HIV. It is never used alone. It is always one part of a combination regimen, because HIV quickly becomes resistant to a single drug. Like other HIV treatments, it does not cure the infection, but by keeping the virus under control it protects the immune system, lowers the chance of HIV-related illness and reduces the risk of passing HIV to others. Rilpivirine comes in several products with different roles. Edurant is a once-daily tablet taken with other HIV medicines by people starting treatment for the first time, and Edurant PED is a dissolvable version for children aged 2 and older who weigh 14 to under 25 kg. For new starts, it is approved only when the starting viral load (the amount of virus in the blood) is 100,000 copies per milliliter or lower, because treatment failed more often at higher levels. Rilpivirine is also built into complete one-product regimens. Odefsey and Complera combine it with two other HIV medicines in a single daily tablet. Juluca pairs it with dolutegravir (an HIV medicine from the integrase inhibitor class, which blocks a different step of the virus's life cycle) and is used to switch adults whose virus is already well controlled. Cabenuva pairs long-acting rilpivirine with cabotegravir, another integrase inhibitor, as injections every one or two months, for adults and adolescents 12 and older (at least 35 kg) whose virus is already suppressed on stable treatment.
To multiply, HIV has to copy its genetic material into a form that can be inserted into a person's immune cells. It uses an enzyme called reverse transcriptase to do this. Rilpivirine belongs to a class called non-nucleoside reverse transcriptase inhibitors (NNRTIs): it attaches to that enzyme and stops it working, so the virus cannot make new copies of itself. With fewer new copies, the amount of virus in the blood falls, often to levels that standard tests cannot detect, and the immune system's CD4 cells (the white blood cells HIV destroys) can recover. Partner drugs in the regimen block the virus at other steps, which is why the combination works and why resistance is much less likely than with any one drug.
The Edurant tablet is 25 mg taken once a day, and it must be taken with a meal. Taken on an empty stomach, the body absorbs roughly 40% less of it, and a protein shake on its own does not count as a meal. Lower levels can allow the virus to rebound and develop resistance, so the meal requirement matters more than it might seem. Combination tablets that contain rilpivirine, such as Odefsey and Complera, are also taken once daily with a meal. Edurant PED tablets are dissolved in a small amount of water and taken immediately with a meal, at a dose based on the child's weight. The two forms are not interchangeable milligram for milligram, so a child who reaches 25 kg needs a new prescription for the regular tablet. It is worth checking the tablets each time a prescription is filled. Cabenuva is given by a clinician as two injections into the buttock muscles, monthly, or every two months, after one or two starting visits with larger doses. Some people first take rilpivirine and cabotegravir as tablets for about a month to check tolerability. Keeping every injection appointment is essential, and if a visit has to be missed, the care team can plan a short course of tablets to cover the gap. Doses of rilpivirine are not changed without the prescriber. With Edurant tablets, the tuberculosis drug rifabutin requires a temporary dose increase; rifabutin cannot be used with Cabenuva.
The most common side effects of rilpivirine tablets are headache, trouble sleeping, low mood and mild rash, which usually appears in the first four to six weeks. For people receiving Cabenuva, soreness at the injection site is very common. In studies most people had some pain, swelling or a lump where the shot was given, typically mild to moderate and lasting about three days. Some people also have fever, tiredness or muscle aches after injections. Depression and mood changes have been reported, and occasionally suicidal thoughts. Severe low mood or thoughts of suicide need immediate medical evaluation, so contact the care team right away rather than waiting for the next visit. Rarely, rilpivirine causes a serious allergic or skin reaction, including one called DRESS that can affect the liver and other organs. Stop the medicine and seek medical attention promptly if a rash comes with fever, blisters, mouth sores, red or inflamed eyes, swelling of the face, or yellowing of the skin or eyes. Swelling of the lips, tongue or throat with difficulty breathing or swallowing is an emergency. Rilpivirine can also affect the liver, and people with hepatitis B or C or with high liver enzymes before starting have regular liver blood tests. Uncommonly, within minutes of a Cabenuva injection, people have had shortness of breath, abdominal cramping, flushing, sweating or numbness in the mouth. Clinics watch people for about 10 minutes afterward for this reason.
Some medicines lower rilpivirine levels enough for HIV treatment to fail and for the virus to become resistant. Rilpivirine tablets should not be combined with proton pump inhibitors, the acid-reducing medicines such as omeprazole (Prilosec), esomeprazole (Nexium) and pantoprazole, because rilpivirine needs stomach acid to be absorbed. Other acid reducers can be used with the tablets with careful timing: antacids such as Tums at least 2 hours before or 4 hours after rilpivirine, and H2 blockers (a milder class of acid reducer) such as famotidine (Pepcid) at least 12 hours before or 4 hours after. Rilpivirine also must not be taken with the seizure medicines carbamazepine, oxcarbazepine, phenobarbital or phenytoin, the tuberculosis antibiotics rifampin or rifapentine, more than a single dose of the steroid dexamethasone, or the herbal supplement St. John's wort. At high levels, rilpivirine can affect the heart's electrical rhythm, so prescribers may choose alternatives to other medicines with that effect, including some antibiotics such as clarithromycin and erythromycin. People taking methadone may need their dose monitored. Because the list of interactions is long, the HIV team and pharmacist should review every new prescription, over-the-counter product and supplement. Combination products bring their partner drugs' warnings. For people who also have hepatitis B, stopping Odefsey or Complera can cause a severe flare of hepatitis B, because their partner medicines (emtricitabine and tenofovir) also hold hepatitis B in check, so these should not be stopped without a plan and follow-up liver tests. In pregnancy, rilpivirine levels run lower, so people who are already well controlled on Edurant usually continue it with closer viral load checks. Rilpivirine passes into breast milk, and infant feeding is worth discussing with the HIV team.
Rilpivirine is a long-term medicine. HIV treatment is meant to be continued indefinitely, because the virus returns when medicines stop. After starting, viral load blood tests show whether the regimen is working, usually with the goal of an undetectable level, and once control is stable the tests become less frequent. Starting HIV treatment can sometimes reawaken an old hidden infection as the immune system recovers, so new signs of infection in the first months are worth reporting. For tablets, the practical work is consistency: one dose a day, always with a meal, and planning around acid reducers. For Cabenuva, the trade-off is fewer pills for a fixed injection schedule and a few days of soreness after each visit. Its medicine stays in the body for 12 months or longer after the last injection. If someone stops, a full replacement regimen has to begin within the time the care team specifies, or low lingering levels can let resistant virus develop. If viral load rises, the team will check adherence, food timing, interactions and resistance before deciding whether to change treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Rilpivirine, what you've noticed, or ask the community a question.